Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment

International Journal of Radiation Oncology Biology Physics

Volumn 85, Issue 5, 2013, Pages 1340-1345

  Jagdis, Amanda ^a   Phan, Tien ^b,c   Klimowicz, Alexander C ^b,c   Laskin, Janessa J ^a,d   Lau, Harold Y ^b,c   Petrillo, Stephanie K ^b   Siever, Jodi E ^e   Thomson, Thomas A ^a,d   Magliocco, Anthony M ^b,c   Hao, Desirée ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e ALBERTA HEALTH SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; LOCOREGIONAL RECURRENCE; METHODS AND MATERIALS; NASOPHARYNGEAL CARCINOMA; PROTEIN EXPRESSION LEVELS; PROTEIN EXPRESSIONS; WORLD HEALTH ORGANIZATION;

ANTIBODIES;

PATIENT TREATMENT;

CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; NUCLEIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP F PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; WORLD HEALTH ORGANIZATION; XERODERMA PIGMENTOSUM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84875254405     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.09.032     Document Type: Article

References (20)

1. A. Ahmad, A.R. Robinson, and A. Duensing ERCC1-XPF endonuclease facilitates DNA double strand break repair Mol Cell Biol 28 2008 5082 5092
2. K. Kirschner, and D.W. Melton Multiple roles of ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs Anticancer Res 30 2010 3223 3232
3. S. Arora, A. Kothandapani, and K. Tillison Downregulation of ERCC1-XPF enhances cisplatin efficacy in cancer cells DNA Repair 9 2010 745 753
4. Z.H. Siddik Cisplatin resistance, molecular basis of a multifaceted impediment B. Teicher, Cancer drug discovery and development: Cancer drug resistance 2006 Humana Press Totowa, NJ 283 308
5. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non small cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991
6. S. Usanova, A. Piee-Staffa, and U. Sied Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression Mol Cancer 16 2010 248 259
7. D. Sprong, H. Janssen, and C. Vens Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status Int J Radiat Oncol Biol Phys 64 2006 562 572
8. J. Carles, M. Monzo, and M. Amat Single nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with stage I to II head-and-neck cancer Int J Radiat Oncol Biol Phys 66 2006 1022 1030
9. C. Doll, M. Prystajecky, and M. Eliasziw Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone Radiother Oncol 97 2010 352 359
10. N. Graf, W. Ang, and G. Zhu Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity Chembiochem 12 2011 1115 1123
11. B. Alexander, K. Sprott, and D. Farrow DNA repair protein biomarkers associated with time to recurrence in triple negative breast cancer Clin Cancer Res 16 2010 5796 5804
12. H.W. Lee, Y.H. Hwanga, and J.H. Han High expression of excision repair cross-complementation group1 protein predicts poor outcome in patients with nasopharyngeal cancer Oral Oncol 46 2010 209 213
13. S.H. Chan, F.M. Cheung, and W.T. Ng Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys 79 2011 1414 1420
14. J.M. Sun, M.J. Ahn, and M.J. Park Expression of excision repair cross complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy Int J Radiat Oncol Biol Phys 80 2011 655 660
15. N. Bhagwat, V. Roginskaya, and M. Acquafondata Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue Cancer Res 69 2009 6831 6837
16. D. Hao, H.Y. Lau, and M. Eliasziw Comparing ERCC1 protein expression, mRNA levels and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status Head Neck 34 2012 785 791
17. M. Biggerstaff, D.E. Szymkowski, and R.D. Wood Co-correction of the ERCC1, ERCC4 and xeroderma pigmentosum group F DNA repair defects in vitro. EMBO J 12 1993 3685 3692
18. K.A. Olaussen, and J.C. Soria Validation of ERCC1-XPF immunodetection [letter] Cancer Res 70 2010 3851 3852
19. N.G.J. Jaspers, A. Raams, and M.C. Silengo First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severed developmental failure Am J Hum Genet 80 2007 457 466
20. A. Anwaar, J.H. Enzlin, and N.R. Baghwat Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients PLoS Genet 6 2010 e1000871